Payment overview · 2025
General Payments
$2,847.59
175 reported records · 26 companies
Healthcare provider profile · identity verified
Baxter Drew Wellmon, DO
Allopathic & Osteopathic Physicians|Family Medicine · SHIPPENSBURG, PA · NPI 1518007020
Verified facts
What the public records show
CMS Open Payments records show Baxter Drew Wellmon, DO received $2,847.59 in general payments during 2025 across 175 reported records.
ABBVIE INC. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 52 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 638 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 638 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $384.07 | 13.5% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $382.20 | 13.4% | 26 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $341.40 | 12.0% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $183.83 | 6.5% | 15 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $169.02 | 5.9% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $160.91 | 5.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.86 | 5.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.86 | 4.8% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $129.97 | 4.6% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.97 | 3.4% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.28 | 3.2% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $84.82 | 3.0% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $80.38 | 2.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.23 | 2.5% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $54.02 | 1.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.86 | 1.8% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.88 | 1.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.02 | 1.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.18 | 1.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.08 | 1.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $31.56 | 1.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.56 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.40 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.67 | 0.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.04 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,847.59 | 175 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $246.73 | 18 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $169.02 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $161.94 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $155.98 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $150.09 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.31 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.47 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $129.97 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $117.82 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $117.44 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $115.12 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $109.11 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $108.26 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $106.68 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $98.46 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.32 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $90.28 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $88.24 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.24 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $84.82 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $81.82 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $81.82 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $80.38 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.53 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $68.53 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.38 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.38 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.38 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $54.02 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $49.86 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $49.62 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.47 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $42.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.18 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 638 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 202 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
638 | 80 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
93 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
638 | 80 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 970 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 903 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 861 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 781 | 136 |
| Lisinopril | Lisinopril | 717 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 715 | 176 |
| Sertraline Hcl | Sertraline Hcl | 713 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 667 | 148 |
| Eliquis | Apixaban | 638 | 80 |
| Losartan Potassium | Losartan Potassium | 634 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 595 | 122 |
| Buspirone Hcl | Buspirone Hcl | 588 | 108 |
| Famotidine | Famotidine | 568 | 101 |
| Gabapentin | Gabapentin | 520 | 97 |
| Potassium Chloride | Potassium Chloride | 438 | 80 |
| Trazodone Hcl | Trazodone Hcl | 424 | 85 |
| Omeprazole | Omeprazole | 422 | 96 |
| Quetiapine Fumarate | Quetiapine Fumarate | 422 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 393 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 353 | 77 |
| Mirtazapine | Mirtazapine | 347 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 341 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 332 | 63 |
| Meloxicam | Meloxicam | 326 | 90 |
| Metformin Hcl | Metformin Hcl | 326 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 93 |
| Donepezil Hcl | Donepezil Hcl | 300 | 37 |
| Allopurinol | Allopurinol | 298 | 54 |
| Memantine Hcl | Memantine Hcl | 274 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 260 | 59 |
| Warfarin Sodium | Warfarin Sodium | 256 | 29 |
| Spironolactone | Spironolactone | 247 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 241 | 56 |
| Simvastatin | Simvastatin | 210 | 40 |
| Jardiance | Empagliflozin | 202 | 42 |
| Prednisone | Prednisone | 201 | 89 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 200 | 98 |
| Montelukast Sodium | Montelukast Sodium | 193 | 49 |
| Carvedilol | Carvedilol | 191 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 190 | 25 |
| Divalproex Sodium | Divalproex Sodium | 188 | 28 |
| Celecoxib | Celecoxib | 185 | 56 |
| Glimepiride | Glimepiride | 178 | 42 |
| Tramadol Hcl | Tramadol Hcl | 175 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 173 | 25 |
| Lorazepam | Lorazepam | 170 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 159 | 29 |
| Bumetanide | Bumetanide | 156 | 27 |
| Cephalexin | Cephalexin | 145 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 139 | 24 |
| Alendronate Sodium | Alendronate Sodium | 138 | 28 |
| Cefdinir | Cefdinir | 133 | 98 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 42 |
| Levetiracetam | Levetiracetam | 120 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 20 |
| Alprazolam | Alprazolam | 114 | 30 |
| Finasteride | Finasteride | 111 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 40 |
| Latanoprost | Latanoprost | 102 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 100 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 99 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 98 | 20 |
| Olanzapine | Olanzapine | 96 | 13 |
| Ezetimibe | Ezetimibe | 95 | 28 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 93 | 75 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 90 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 42 |
| Ozempic | Semaglutide | 86 | 20 |
| Xarelto | Rivaroxaban | 86 | 18 |
| Atenolol | Atenolol | 83 | 14 |
| Bupropion Xl | Bupropion Hcl | 83 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 17 |
| Nyamyc | Nystatin | 80 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 47 |
| Baclofen | Baclofen | 76 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 12 |
| Metformin Hcl Er | Metformin Hcl | 76 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 73 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 46 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 72 | 12 |
| Digoxin | Digoxin | 71 | suppressed |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Risperidone | Risperidone | 69 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 17 |
| Pregabalin | Pregabalin | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 62 | 13 |
| Trulicity | Dulaglutide | 59 | 12 |
| Rivastigmine | Rivastigmine | 58 | suppressed |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Telmisartan | Telmisartan | 51 | 14 |
| Rybelsus | Semaglutide | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Valsartan | Valsartan | 48 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 46 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 45 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 16 |
| Metolazone | Metolazone | 41 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Rytary | Carbidopa/Levodopa | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 37 | 13 |
| Mometasone Furoate | Mometasone Furoate | 36 | 24 |
| Novolog Flexpen | Insulin Aspart | 36 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 13 |
| Azithromycin | Azithromycin | 35 | 29 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Repaglinide | Repaglinide | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 20 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Loperamide | Loperamide Hcl | 32 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 16 |
| Levofloxacin | Levofloxacin | 31 | 18 |
| Nystatin | Nystatin | 30 | 16 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 17 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 17 |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 17 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Neurontin | Gabapentin | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 22 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 21 | 16 |
| Dutasteride | Dutasteride | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Monoject Insulin Safety Syrng | Syringe With Needle, Insulin | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,847.59 · 175 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, BEXSERO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, EVENITY, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PEDIARIX, PENMENVY, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error